Monopar Therapeutics
MNPR
Monopar Therapeutics (MNPR) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Downgraded | Overweight → Neutral | $119.00 from $109.00 | Aug 13, 2026 |
| Barclays | Maintained | Overweight | $128.00 from $125.00 | Aug 13, 2026 |
| BTIG | Maintained | Buy | $133.00 from $117.00 | Aug 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $125.00 from $105.00 | Jul 22, 2026 |
| BTIG | Maintained | Buy | $117.00 from $104.00 | Jun 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $105.00 | Jun 29, 2026 |
| Chardan Capital | Maintained | Buy | $100.00 | Mar 30, 2026 |
| BTIG | Maintained | Buy | $104.00 | Feb 23, 2026 |
| BTIG | Maintained | Buy | $104.00 | Feb 2, 2026 |
| Chardan Capital | Maintained | Buy | $100.00 | Jan 29, 2026 |
| BTIG | Maintained | Buy | $104.00 | Jan 14, 2026 |
| Morgan Stanley | Initiated Coverage | Overweight | $115.00 | Jan 9, 2026 |
| Raymond James | Downgraded | Strong Buy → Outperform | $123.00 from $142.00 | Nov 14, 2025 |
| Chardan Capital | Maintained | Buy | $100.00 | Nov 13, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $115.00 | Nov 10, 2025 |
| Chardan Capital | Maintained | Buy | $100.00 from $85.00 | Nov 9, 2025 |
| Barclays | Initiated Coverage | Overweight | $125.00 | Oct 13, 2025 |
| Raymond James | Maintained | Strong Buy | $142.00 from $80.00 | Oct 6, 2025 |
| Oppenheimer | Maintained | Outperform | $115.00 from $77.00 | Oct 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $105.00 from $70.00 | Sep 29, 2025 |
Frequently asked questions
What is the latest analyst rating on MNPR?
On Aug 13, 2026, Cantor Fitzgerald downgraded Monopar Therapeutics to Neutral with a price target of $119.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.